Corbus Pharmaceuticals Holdings, Inc. announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application of CRB-601, a potentially best-in-class TGFß blocking monoclonal antibody targeting the integrin avß8. Pre-clinical data presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrates CRB-601 overcame tumor immune exclusion and enhanced the activity of immune checkpoint inhibitors in vivo. The Company expects to enroll the first participant in a Phase 1 study in the first half of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.02 USD | +8.80% | +0.04% | +645.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+645.36% | 473M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- CRBP Stock
- News Corbus Pharmaceuticals Holdings, Inc.
- Corbus Pharmaceuticals Holdings, Inc. Announces FDA Clearance of IND Application for its Anti-avb8 Monoclonal Antibody (CRB-601)